Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
Supreme Court ruled Remsima trademark is okay
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Dec 24, 2014 10:34:41
The Supreme Court dismissed Janssen Korea’s trademark case against Celltrion, ruling that Celltrion didn’t infringe Janssen Korea’s right on the trademark of Remicade obviously.

Janssen insisted that Celltrion imitated Janssen’s trademark of Remicade for the trademark of its Remsima, but lower courts dismissed the case all together.

As the Supreme Court now decided not to review the case, Celltrion will keep the trademark right on Remsima.

Remsima, a biosimilar of Remicade, has been marketed since the second half of 2013. Remsima sales are rapidly growing in South Korea.

Resima was rolled out in Japan and are approved for marketing in Europe. Celltrion is also working to have its Remsima approved in the U.S.
Reply 0
Name Password
Popular News
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com